Head and Neck Cancer Drug Development Summit

3 years ago Posted By : User Ref No: WURUR85058 0
  • Image
  • TypeConference
  • Image
  • Location Online Event
  • Price
  • Date 30-11-2021 - 01-12-2021
Head and Neck Cancer Drug Development Summit, Online Event
Conference Title
Head and Neck Cancer Drug Development Summit
Event Type
Conference
Conference Date
30-11-2021 to 01-12-2021
Location
Online Event
Organization Name / Organize By
Hanson Wade
Organizing/Related Departments
Hanson Wade
Organization Type
Event Organizing Company
ConferenceCategory
Non Technical
ConferenceLevel
All (State/Province/Region, National & International)
Related Industries

Medical/Healthcare/Hospital

Location
Online Event

The Head and Neck Cancer Drug Development Summit has been curated with the industry in mind. Development in the head and neck cancer space has entered the most active period to date, with emerging immunotherapy biotechs, leading biopharma companies, and pioneering academics racing to exploit this immunogenic tumor, validate early clinical data from broader solid tumor trials, and improve clinical outcomes in this indication with a high unmet medical need. 

Join the only dedicated forum tackling critical challenges in head and neck cancer including:
  
-Analyzing the role of the tumor in pathogenesis and treatment response
-Understanding the mechanisms of inherent and acquired resistance  
-Discovering where promising avenues for targeted drug approaches for both HPV-positive and -negative subtypes are
-Uncovering how we can tailor the treatment journey to leverage the advantages of HPV-specific immunotherapy, immune checkpoint inhibitors, chemoradiotherapy, and improve patient outcomes

Download the full event guide to learn more about our expert speaker faculty and all agenda topics to be covered at this year's summit https://ter.li/nilxm1

Speakers: Lars Birgerson, Chief Executive Officer, Adlai Nortye, Sophia Randolph, Chief Medical Officer, Alexo Therapeutics Inc., Michael Needle, Chief Medical Officer, AVEO Oncology, Ahmed Tajmohame, Researcher, Beacon Targeted Therapies, Anish Suri, Chief Scientific Officer and President, Cue Biopharma, Jon Wigginto, Chief Medical Officer Portfolio, Cullinan Oncology, Frederic Triebel, Chief Scientific Officer and Chief Medical Officerm Immutep, Jessica Sorrentino, Senior Director Translational Medicine, Istari Oncology, Anthony Sale, CEO, MiRecule Inc., Marshall Posner, Professor - Medicine, Mount Sinai School of Medicine, Mary Tagliaferri, SVP and Executive Clinical Fellow, Nektar, Miguel Garcia-Guzman, Chief Scientific Officer, Rakuten Medical, Maire-Louis, Fjaellskog Chief Medical Officer, Sensei Bio, Jens Bjorheim, Chief Medical Officer, Ultimovacs, Siri Torhaug, Chief Medical Officer, Vaccibody, Terrance Fisher, VP Clinical Science, VaccineX, Jan Davidson, Chief Medical Officer, Wugen Inc.

Others Details

Brochure: https://go.evvnt.com/842127-0?pid=6581

Registration Fees
Available
Registration Fees Details
Industry Rate - Early Bird 1 Pricing (save $500): USD 1599.00, Industry Rate - Final Price: USD 2099.00, Solution Provider Rate - Early Bird 1 Pricing (save $700): USD 1899.00, Solution Provider Rate - Final Price: USD 2599.00
Registration Ways
Website
Address/Venue
Online  Virtual 
Contact
Customer Service

[email protected]

     (+1) 617 455 4188